Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experience
Roelf Valkema(Active Medicine (United Kingdom)), Eric P. Krenning(Cyclotron (Netherlands)), Marion de Jong(Shell (Netherlands)), Boen L.R. Kam(Erasmus MC), Mats Stridsberg(Uppsala University Hospital), Pieternella J. Lugtenburg(Erasmus MC Cancer Institute), Frank H. de Jong(Uppsala University Hospital), Arjan Christiansen(Uppsala University Hospital), Willem H. Bakker(Erasmus MC), Wout A. P. Breeman(Uppsala University Hospital), Geert Ensing(Uppsala University Hospital), Jan Lindemans(Unknown), P.P.M. Kooij(Erasmus MC), Wouter W. de Herder(Erasmus University Rotterdam)
Cited by 433
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and Survival
|Journal of Clinical Oncology|2008|1.4k
ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary
|Neuroendocrinology|2012|869
The Role of Somatostatin and Its Analogs in the Diagnosis and Treatment of Tumors
|Endocrine Reviews|1991|814